TimothySteinhoffMD
Psychiatry • Boston, MAPsycho-Oncology, Psychosomatic Medicine
Psychosocial Oncology and Palliative Care Dana-Farber Cancer Institute
Dr. Steinhoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6181
Education & Training
Brigham and Women's HospitalFellowship, Consultation-Liaison Psychiatry, 2020 - 2021
Dana-Farber Cancer InstituteFellowship, Psychosocial Oncology, 2020 - 2021
Butler Hospital/Brown UniversityChief Residency, Psychiatry, 2019 - 2020- Butler Hospital/Brown UniversityResidency, Psychiatry, 2017 - 2020
- Brown University (Butler Hospital)Residency, Psychiatry/Neurology, 2015 - 2017
Lewis Katz School of Medicine at Temple UniversityClass of 2015
Certifications & Licensure
RI State Medical License 2015 - 2026
MA State Medical License 2020 - 2025- American Board of Psychiatry and Neurology Psychiatry
- American Board of Psychiatry and Neurology Consultation-Liaison Psychiatry
Publications & Presentations
PubMed
- 26 citationsCharacteristics and quality of autism websites.Brian Reichow, Timothy B. Steinhoff, Nicole Letsinger, Adam J. Naples, Fred R. Volkmar
Journal of Autism and Developmental Disorders. 2012-06-01 - 3 citationsBrief Report: Consistency of Search Engine Rankings for Autism WebsitesBrian Reichow, Timothy B. Steinhoff, Jason I. Halpern, Fred R. Volkmar
Journal of Autism and Developmental Disorders. 2012-02-21 - Palliative care tumor board: a narrative review and presentation of a novel conference to enhance collaboration and coordination of pain and symptom management for pat...Dana Guyer, Timothy Steinhoff, Aaron W P Maxwell, Tara Szymanski, Sahar Shahamatdar
Annals of Palliative Medicine. 2024-05-01
Journal Articles
- Tumefactive Demyelination with White Matter Necrosis Following Cessation of Natalizumab TreatmentSteinhoff T and Scott T, Neurological Cases, 3/4/2015
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
